Sorrento Therapeutics Statistics
Sorrento Therapeutics (SRNE) Stock Statistics & Valuation Metrics
Total Valuation
Sorrento Therapeutics has a market cap or net worth of $165.38K. The enterprise value is $331.48M.
- Market Cap
- $165.38K
- Enterprise Value
- $331.48M
Share Statistics
Sorrento Therapeutics has 551,281,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 551,281,100
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Sorrento Therapeutics’s return on equity (ROE) is 30.79 and return on invested capital (ROIC) is -286.80%.
- Return on Equity (ROE)
- 30.79
- Return on Assets (ROA)
- -1.21
- Return on Invested Capital (ROIC)
- -286.80%
- Return on Capital Employed (ROCE)
- -3.48
- Revenue Per Employee
- 66.22K
- Profits Per Employee
- -603.63K
- Employee Count
- 949
- Asset Turnover
- 0.13
- Inventory Turnover
- 3.35
Valuation Ratios
The current PE Ratio of Sorrento Therapeutics is -0.00. Sorrento Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.01
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Sorrento Therapeutics had revenue of 62.84M and earned -572.84M in profits. Earnings per share was -1.37.
- Revenue
- 62.84M
- Gross Profit
- 29.39M
- Operating Income
- -504.31M
- Pretax Income
- -561.75M
- Net Income
- -572.84M
- EBITDA
- -539.93M
- Earnings Per Share (EPS)
- -1.37
Cash Flow
In the last 12 months, operating cash flow was -234.63M and capital expenditures -8.59M, giving a free cash flow of -243.21M billion.
- Operating Cash Flow
- -234.63M
- Free Cash Flow
- -243.21M
- Free Cash Flow per Share
- -0.73
Dividends & Yields
Sorrento Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -139454.54%
- Earnings Yield
- -341535.00%
Stock Price Statistics
- Beta
- -0.86
- 52-Week Price Change
- -94.05%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Sorrento Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 10, 2023
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Sorrento Therapeutics as a current ratio of 0.29, with Debt / Equity ratio of -722.95%
- Current Ratio
- 0.29
- Quick Ratio
- 0.26
- Debt to Market Cap
- 9.53
- Net Debt to EBITDA
- -0.21
- Interest Coverage Ratio
- -58.82
Taxes
In the past 12 months, Sorrento Therapeutics has paid -2.42M in taxes.
- Income Tax
- -2.42M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Sorrento Therapeutics EV to EBITDA ratio is -0.21, with an EV/FCF ratio of -0.36.
- EV to Sales
- 1.77
- EV to EBITDA
- -0.21
- EV to Free Cash Flow
- -0.36
- EV to Operating Cash Flow
- -0.38
Balance Sheet
Sorrento Therapeutics has $80.64M in cash and marketable securities with $207.60M in debt, giving a net cash position of -$126.97M billion.
- Cash & Marketable Securities
- $80.64M
- Total Debt
- $207.60M
- Net Cash
- -$126.97M
- Net Cash Per Share
- -$0.23
- Tangible Book Value Per Share
- -$0.73
Margins
Gross margin is 46.77%, with operating margin of -802.55%, and net profit margin of -911.60%.
- Gross Margin
- 46.77%
- Operating Margin
- -802.55%
- Pretax Margin
- -893.95%
- Net Profit Margin
- -911.60%
- EBITDA Margin
- -859.22%
- EBIT Margin
- -880.30%
